Neos Therapeutics, Inc. (NASDAQ: NEOS) (“Neos” or “the Company”) today
announced the closing of its initial public offering of 5,520,000 shares
of its common stock at an initial public offering price of $15.00 per
share, which includes the exercise in full by the underwriters of their
option to purchase up to 720,000 additional shares of common stock. All
of the shares in the offering were offered by Neos. The shares of Neos’
common stock began trading on the NASDAQ Global Market on July 23, 2015
under the ticker symbol “NEOS.” Including proceeds from the sale of the
additional shares subject to the underwriters’ option, the gross
proceeds from the initial public offering were $82.8 million, before
deducting underwriting discounts and commissions and offering expenses.
UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted
as joint book-running managers and JMP Securities acted as a lead
manager for the offering.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on July 22, 2015.
This offering was made solely by means of a prospectus. Copies of the
final prospectus relating to the offering may be obtained from the
offices of UBS Securities LLC, Attention: Prospectus Department, 1285
Avenue of the Americas, New York, NY 10019, or by telephone: (888)
827-7275; BMO Capital Markets Corp., 3 Times Square, New York, NY 10036,
Attention: Equity Syndicate Department, Telephone: (800) 414-3627,
Email: bmoprospectus@bmo.com;
or RBC Capital Markets, LLC, Attention: Prospectus Department, 200 Vesey
Street, 8th Floor, New York, NY 10281.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or jurisdiction.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on
developing, manufacturing and commercializing products utilizing its
proprietary modified‐release drug delivery technology platform. The
Company is initially focusing on ADHD and has developed three branded
product candidates that are XR medications in patient‐friendly ODT or
liquid suspension dosage forms. In addition, Neos manufactures and
markets its generic equivalent of the branded product Tussionex®, an XR
liquid suspension of hydrocodone and chlorpheniramine indicated for the
relief of cough and upper respiratory symptoms of a cold.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150728006664r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20150728006664/en/
Copyright Business Wire 2015